Determination of the Rituximab Binding Site to the CD20 Epitope Using SPOT Synthesis and Surface Plasmon Resonance Analyses

Antibodies not only play a major role in clinical diagnostics and biopharmaceutical analysis but also are class of drugs that regularly used to treat numerous diseases. The identification antibody-epitope binding sites is then great interest many emerging medical bioanalytical applications, particularly design monoclonal antibodies (mAb) mimics taking advantage amino acid residues involved the binding. Among relevant antibodies, antibody rituximab has received significant attention as it exploited several cancers including non-Hodgkin's lymphoma chronic lymphocytic leukemia, well some autoimmune disorders such rheumatoid arthritis. targeted cells occurs via recognition CD20 epitope. A crystallographic study shown area, named paratope, located at surface rituximab. Combining SPOT method complementary plasmon resonance technique allowed us detect an extended domain buried pocket Fab formed by four β-sheets. More generally, present offers comprehensive approach identify sites.